高级检索
当前位置: 首页 > 详情页

Malignancy risk stratification for solitary pulmonary nodule: A clinical practice guideline

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China [2]Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China [3]Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Cochrane China Ctr, Chengdu, Peoples R China [4]Sichuan Univ, West China Hosp, MAGIC China Ctr, Chengdu, Peoples R China [5]Natl Med Prod Adm NMPA, Key Lab Real World Data Res & Evaluat Hainan, Chengdu, Peoples R China [6]Sichuan Ctr Technol Innovat Real World Data, Chengdu, Peoples R China [7]Sichuan Univ, West China Hosp, Dept Nucl Med, Chengdu, Peoples R China [8]Sichuan Univ, West China Hosp, Ctr Gerontol & Geriatr, Natl Clin Res Ctr Geriatr, Chengdu, Peoples R China [9]McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada [10]Cent South Univ, Xiangya Hosp, Branch Natl Clin Res Ctr Resp Dis, Dept Resp Med,Natl Key Clin Specialty, Changsha, Peoples R China [11]Army Med Univ, Affiliated Hosp 2, Inst Resp Dis, Chongqing, Peoples R China [12]Fudan Univ, Dept Radiol, Huadong Hosp, Shanghai, Peoples R China [13]Chinese Peoples Liberat Army Gen Hosp, Dept Resp Med, Beijing, Peoples R China [14]First Affiliated Hosp, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis, Guangzhou, Peoples R China [15]Air Force Med Univ, Xijing Hosp, Dept Pulm & Crit Care Med, Xian, Peoples R China [16]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Resp & Crit Care Med, Shanghai, Peoples R China [17]Nanchong Cent Hosp, North Sichuan Med Coll, Dept Respirat, Clin Med Coll 2, Nanchong, Peoples R China [18]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China [19]Dalian Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Dalian, Peoples R China [20]Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Resp & Crit Care Med, Peoples Hosp, Zhengzhou, Peoples R China [21]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Resp Med, Wuhan, Peoples R China [22]Army Med Univ, Daping Hosp, Dept Resp Dis, Chongqing, Peoples R China [23]Nanjing Univ, Jinling Hosp, Dept Resp & Crit Med, Med Sch, Nanjing, Peoples R China
出处:
ISSN:

关键词: clinical practice guideline malignancy risk stratification solitary pulmonary nodule

摘要:
Clinical question The detection rate of the solitary pulmonary nodule (SPN) is increasing with the popularization of CT scanning. Malignancy risk stratification for SPN is a major clinical difficulty. Current practice There have been several guidelines for SPN assessment. Inconsistency of these guidelines makes the clinical application difficult and confusing. Recommendations In this Rapid Recommendation, solid and subsolid SPNs are recommended to be evaluated respectively. Six factors, namely the combination of age with sex, smoking history, history of malignancy, family history of malignancy, and nodule size, are recommended for malignancy risk stratification for both kinds of SPNs; the border of nodules (spiculation and lobulation) is recommended for evaluating solid SPNs and the density of nodules (pure or mixed ground-glass nodule) is recommended for subsolid nodules. Among them, smoking history and radiologic features (nodule diameter, border, and density) are of relatively higher importance. A scoring system was proposed to assist malignancy risk stratification of SPNs, with a total score ranging from six points to 15 points (if solid) or 17 points (if subsolid). For each SPN, regardless of solid or subsolid in nature, a total score of <= 7 points suggested a low risk of being malignant, while 7 to 9 points suggested medium risk, and >= 9 points suggested high risk. How this guideline was created This rapid recommendation was developed using the MAGIC (Making GRADE the Irresistible Choice) methodological framework. First, a clinical subcommittee identified the topic of recommendation and requested evidence. Then, an independent evidence synthesis subcommittee performed a comprehensive literature review and evaluated the evidence. Finally, based on findings from the systematic review and use of real-world data, the clinical subcommittee formulated recommendations, including the scoring system, through a consensus procedure. The evidence A total of 13857 patients with SPNs were included in the meta-analysis and the association between 12 candidate factors and the risk of SPNs being malignant was studied. Eventually, seven factors were recommended for SPNs evaluation, and a scoring system was proposed. Understanding the recommendation The parameters included are objective. Therefore, this recommendation is feasible in clinical practice. However, there are several uncertainties, such as a lack of further verification. It might be misclassified by the scoring system. Clinicians could choose the most suitable scheme according to the recommendation, along with their own experience in specific situations.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
JCR分区:
出版当年[2022]版:
Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China [2]Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China [2]Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China [3]Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Cochrane China Ctr, Chengdu, Peoples R China [4]Sichuan Univ, West China Hosp, MAGIC China Ctr, Chengdu, Peoples R China [5]Natl Med Prod Adm NMPA, Key Lab Real World Data Res & Evaluat Hainan, Chengdu, Peoples R China [6]Sichuan Ctr Technol Innovat Real World Data, Chengdu, Peoples R China [*1]Evidence-Based Medicine Center, Cochrane China Center andMAGIC China Center,West China Hospital, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan, China [*2]Department of Respiratory and Critical CareMedicine,West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号